More trouble for embattled EpiPen maker Mylan . Two U.S. senators claim Mylan overcharged Medicaid for some twenty years to the tune of millions of dollars. The lawmakers say the EpiPen was misclassified as a generic drug. That means Mylan was paying lower rebates to Medicaid, than if the drug was under the brand name category. Mylan came under intense scrutiny for raising the price of the life saving drug. TheStreet’s Scott Gamm reports from Wall Street.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
